Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

× No keyword cloud information.

13 in total

1. Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.

Authors: Jeroen Diepstraten; Christian M Hackeng; Simone van Kralingen; Jiri Zapletal; Eric P A van Dongen; René J Wiezer; Bert van Ramshorst; Catherijne A J Knibbe
Journal: Obes Surg Date: 2012-02-01 Impact factor: 4.129

2. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors: Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal: Chest Date: 2012-02 Impact factor: 9.410

Review 3. Low molecular weight heparins: a guide to their optimum use in pregnancy.

Authors: Pierre Laurent; Guy-Vincent Dussarat; Jacques Bonal; Christophe Jego; Philippe Talard; Christian Bouchiat; Gilles Cellarier
Journal: Drugs Date: 2002 Impact factor: 9.546

Review 4. Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.

Authors: B S Smith; P J Gandhi
Journal: J Thromb Thrombolysis Date: 2001-02 Impact factor: 2.300

Review 5. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors: R Davis; D Faulds
Journal: Drugs Aging Date: 1997-04 Impact factor: 3.923

6. The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task Force.

Authors: B T Colvin; T W Barrowcliffe
Journal: J Clin Pathol Date: 1993-02 Impact factor: 3.411

7. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.

Authors: J C Stiekema; J M Van Griensven; T G Van Dinther; A F Cohen
Journal: Br J Clin Pharmacol Date: 1993-07 Impact factor: 4.335

Review 8. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors: L B Barradell; M M Buckley
Journal: Drugs Date: 1992-11 Impact factor: 9.546

9. Evidence of an absorption phase after short intravenous suramin infusions.

Authors: P R Hutson; K Tutsch; D Spriggs; M Christian; R Rago; R Mutch; G Wilding
Journal: Cancer Chemother Pharmacol Date: 1993 Impact factor: 3.333

Review 10. Low molecular weight heparins. An objective overview.

Authors: D Hoppensteadt; J M Walenga; J Fareed
Journal: Drugs Aging Date: 1992 Sep-Oct Impact factor: 3.923